|
|
|
|
|
by haldujai
997 days ago
|
|
You’re looking at the wrong metric and misinterpreting the stats, not only is overall survival not a good metric for cancer screening none of the studies are sufficiently powered for OS. What you want to do is look at stage at presentation, treatment costs by stage, and screening costs. These were done for nearly every recommended screening program. The available evidence behind currently recommended screening programs unequivocally shows improved cancer-specific survival and earlier stage at diagnosis. |
|
> What you want to do is
No, what I want to do is assess whether broad screening programs actually make people live longer. Overall survival is the correct metric. Evidence in favor of the claim is lacking.
> none of the studies are sufficiently powered for OS.
"Sufficiently powered" is relative to what size of effect you want to detect--which you haven't specified, so I'm not sure how you can make the assertion that none of the studies are sufficiently powered.
> The available evidence behind currently recommended screening programs unequivocally shows improved cancer-specific survival and earlier stage at diagnosis.
These outcomes ignore negative effects of screening on people who don't have cancer, which is why I'm not interested in them. And yes, there are negative effects, and no, they are not negligible.